COLBY JAMES: Open Payments
NPI 1578193926 · LAYTON, UT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,082 in 65 payments from 9 companies in 2025. Trend: 2023 $2,571 · 2024 $2,384 · 2025 $1,082
Food & beverage: $1,082
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 32 | $354 |
| Janssen Pharmaceuticals, Inc | 15 | $324 |
| Janssen Scientific Affairs, LLC | 1 | $136 |
| Alkermes, Inc. | 10 | $135 |
| Neurocrine BioSciences, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Neuronetics, Inc. | 1 | $29 |
| E.R. Squibb & Sons, L.L.C. | 1 | $19 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $17 |
Products named: VRAYLAR, SPRAVATO, LYBALVI, INVEGA SUSTENNA, INGREZZA, NEUROSTAR TMS THERAPY SYSTEM, COBENFY, REXULTI.
Industry payments across UT — which companies pay providers there.
